KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CRISPR Therapeutics AG (CRSP) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for CRISPR Therapeutics AG (CRSP) over the last 10 years, with Q3 2025 value amounting to 11866.82%.

  • CRISPR Therapeutics AG's EBITDA Margin rose 1760400.0% to 11866.82% in Q3 2025 from the same period last year, while for Sep 2025 it was 1288.25%, marking a year-over-year decrease of 11786800.0%. This contributed to the annual value of 981.74% for FY2024, which is 9450900.0% down from last year.
  • Per CRISPR Therapeutics AG's latest filing, its EBITDA Margin stood at 11866.82% for Q3 2025, which was up 1760400.0% from 23390.47% recorded in Q2 2025.
  • CRISPR Therapeutics AG's EBITDA Margin's 5-year high stood at 84.27% during Q2 2021, with a 5-year trough of 1732650.0% in Q4 2022.
  • Its 5-year average for EBITDA Margin is 122754.75%, with a median of 15452.53% in 2025.
  • Per our database at Business Quant, CRISPR Therapeutics AG's EBITDA Margin tumbled by 2000000000bps in 2022 and then soared by 2000000000bps in 2023.
  • Quarter analysis of 5 years shows CRISPR Therapeutics AG's EBITDA Margin stood at 1128.34% in 2021, then plummeted by -153457bps to 1732650.0% in 2022, then skyrocketed by 100bps to 48.73% in 2023, then tumbled by -365bps to 128.98% in 2024, then plummeted by -9100bps to 11866.82% in 2025.
  • Its last three reported values are 11866.82% in Q3 2025, 23390.47% for Q2 2025, and 15456.76% during Q1 2025.